



Myelodysplastic Syndromes (MDS) Workshop

May 13 - 14, 2024

All times are Eastern Time (ET)

Day 1: Monday – May 13, 2024

8:00 AM Registration

8:30 AM Welcome and Introductory Remarks: Daniel Gallahan

8:45 AM Introduction to MDS, gaps and needs: Guillermo Garcia-Manero

Session 1: Clinical needs – Personalized treatment approaches for MDS/Studies matching new diagnostic approaches with improved treatments

Chairman: Guillermo Garcia-Manero

9:20 AM Presenter: Amer Zeidan - “TP53 mutated MDS, will we make progress?”

9:40 AM Presenter: Monica Guzman - “The epichaperome as a biomarker and therapeutic target”

10:00 AM Presenter: Lukasz Gondek - “Mitochondrial heteroplasmy in the development of MDS”

10:20 AM Presenter: Brett Stevens - “Targeting Unique Metabolic Vulnerabilities in MDS Stem Cells: Bench to Bedside and Back”

10:40 AM Presenter: Russell Rockne - “Predicting leukemia evolution and response to treatment by integrating transition state theory, machine learning, and the peripheral blood transcriptome”

11:00 AM **Session 1 Discussion**

11:20 AM **Break** 15 minutes

Session 2: Genetic predisposition to MDS

Chairman: Lucy Godley

11:35 AM Presenter: Lucy Godley - “Germline predisposition to MDS in adults”

11:55 AM Presenter: Marcin Wlodarski - “Germline and somatic drivers of primary pediatric MDS”

12:15 PM Presenter: Lisa McReynolds - “Using Large Exome Sequencing Cohorts to Evaluate Germline MDS Predisposition Genes”

12:35 PM Presenter: Pinkal Desai - “Clonal Hematopoiesis and CCUS: Mapping progression risk”

12:55 PM Presenter: Tim Chlon - “DDX41 mutations: Splicing anomalies, cellular stress and MDS pathogenesis”

1:15 PM **Session 2 Discussion**

1:35 PM **Lunch** 50 min

Session 3: Analysis of the progression of CHIP to MDS to AML and strategies to intervene, or prevent transformation

Chairman: Daniel Starczynowski

- 2:25 PM** Presenter: Daniel Starczynowski - "Inflammatory Signaling in MDS"
- 2:45 PM** Presenter: Ravi Majeti - "Pre-Leukemic HSCs: Therapeutic Targeting and Clonal Expansion"
- 3:05 PM** Presenter: Brendan Harley - "Building bone marrow"
- 3:25 PM** **Break** 10 minutes
- 3:35 PM** Presenter: Kira Young - "Mechanisms by Which the Aging Microenvironment Drives Progression of CH to MDS"
- 3:55 PM** Presenter: Zuzana Tothova - "Biology and therapeutic targeting of cohesin-mutant myeloid malignancies"
- 4:15 PM** Presenter: Stavroula Kousteni - "Contributions of the stromal microenvironment to MDS pathogenesis; therapeutic implications"
- 4:35 PM** **Session 3 Discussion**
- 5:15 PM** **Adjourn**

Day 2: Tuesday – May 14, 2024

Session 4: Development of preclinical models for the discovery and development of new MDS therapies

Chairman: Peter Aplan

- 9:00 AM** Presenter: Peter Aplan - "Genetically Engineered Mouse (GEM) models for MDS"
- 9:20 AM** Presenter: Laura Calvi - "Modeling niche-clone interactions in vivo: challenges and opportunities"
- 9:40 AM** Presenter: Eirini Papapetrou - "Insights into MDS from human iPSCs"
- 10:00 AM** **Break** 15 minutes
- 10:15 AM** Presenter: Stephanie Halene - "RNA Splicing Factor Mutations in MDS. Do RNA granule perturbations drive clonal advantage?"
- 10:35 AM** Presenter: Justin Taylor - "Altered RNA Export Sensitizes to Nuclear Export Inhibition in SF3B1 Mutant Myelodysplastic Syndromes"
- 10:55 AM** **Session 4 Discussion**
- 11:30 AM** **Workshop Summary and Discussion:** Peter Aplan
- 12:30 PM** **Adjourn**